OraSure Technologies (NASDAQ:OSUR – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday.
Separately, Evercore ISI increased their price target on OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.67.
View Our Latest Stock Analysis on OSUR
OraSure Technologies Stock Up 1.5 %
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $53.35 million. As a group, equities research analysts anticipate that OraSure Technologies will post -0.11 EPS for the current fiscal year.
Hedge Funds Weigh In On OraSure Technologies
Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of OraSure Technologies in the 1st quarter worth about $72,000. Mackenzie Financial Corp purchased a new stake in shares of OraSure Technologies during the second quarter valued at approximately $72,000. Tocqueville Asset Management L.P. increased its holdings in OraSure Technologies by 20.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock worth $93,000 after buying an additional 2,512 shares in the last quarter. Shikiar Asset Management Inc. purchased a new stake in OraSure Technologies during the 2nd quarter valued at $96,000. Finally, SkyView Investment Advisors LLC boosted its holdings in shares of OraSure Technologies by 100.0% in the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 12,000 shares during the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Further Reading
- Five stocks we like better than OraSure Technologies
- Upcoming IPO Stock Lockup Period, Explained
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is the Shanghai Stock Exchange Composite Index?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- When to Sell a Stock for Profit or Loss
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.